Case reports

Specific Antibody Deficiency Presenting With Asthmatic Symptoms (2)

Her pulmonary function test revealed a mild obstruction (FEV1 = 78%, FVC = 76%, FEV1/FVC = 89%) with a reversibility of forced expiratory volume in 1 second FEV1 > 12%. Lung functions were assessed with a spirometer (Sensormedics, S3513, California, USA). Nasal smear cytology revealed normal epithelial cells, skin prick testing was performed with 20 common aeroallergen and positive (histamine) and negative (saline) controls (Stallergenes, France) demonstrating sensitization to house dust mites (Dermatophagoides pteronyssinus:  4x4mm, D.Farrinae:  4x4mm). Her complete blood count values were as follows; haemoglobin: 12.7 mg/dl, leukocyte: 7600 x 103 /ul, thrombocyte count: 323 x 103 /ul, mean corpuscular volume (MCV): 79 fl, absolute neutrophil count: 4900/mm3, absolute monocytes count: 500/mm3 , absolute lymphocyte count: 2000/mm3,  and absolute eosinophil count: 200/mm3. Blood biochemistry, urinary analysis, C-reactive protein and erythrocyte sedimentation rate results were normal. Her chest X-ray was normal. As she had a family history of rheumatic diseases, ANA, Anti-DNA ds, RF were determined and revealed negative results.

The patient was diagnosed as mild persistent asthma and was prescribed intranasal and inhaled corticosteroid therapy (Budesonide 800µg/day), whereby on follow up period of two years, she had two to three asthmatic exacerbations per year despite effective environmental control, good compliance of medication and appropriate usage of inhaler corticosteroid. Her recurrent upper respiratory tract infection, mostly sinusitis, persisted. Other than respiratory and sinusitis infections, she had no other complains with a regular menstruation cycle since she was 12 years old.

* At this point what is your next step for gaining control of the disease and which additional diagnostic studies might be helpful for diagnosis? *
Last updated 16 December 2014
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Send feedback